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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Albuminuria has been proven to be
associated with cardiovascular morbidity
and mortality.
• Such an association has been found not
only in subjects with diabetes and
hypertension, but also in the general
population.
• It could therefore be expected that
especially subjects with higher albuminuria
levels may benefit from blood
pressure-lowering agents to improve their
cardiovascular outcome.
WHAT THIS STUDY ADDS
• This study indicates that the efficacy of
blood pressure-lowering agents to prevent
cardiovascular events is dependent of the
level of albuminuria before start of such
treatment.
• The higher baseline albuminuria, the better
the relative and absolute risk reduction for
cardiovascular events with blood
pressure-lowering drugs.
• The data also suggest a possible better
cardiovascular protective effect of
renin–angiotensin intervening agents
compared with other blood
pressure-lowering agents.
AIMS
Albuminuria has been proven to be associated with cardiovascular (CV) events
in specific patient populations, but also in the general population. This study
aimed to investigate whether the efficacy of blood pressure-lowering agents in
preventing CV events depends on baseline urinary albumin excretion (UAE) and,
if so, whether this holds true for blood pressure-lowering agents in general, or is
limited to agents that interfere in the renin–angiotensin system.
METHODS
Data were used from a community-based cohort study and pharmacy
dispensing records. Included were subjects with hypertension (systolic blood
pressure 140 and/or diastolic blood pressure 90 mmHg), no cardiovascular
disease history, and no previous use of blood pressure-lowering agents.
RESULTS
During study follow-up (7.1 1.6 years), 122 CV events were observed in 1185
subjects included. Start of blood pressure-lowering agents vs. non-use was asso-
ciated with a difference in absolute CV event risk of 0.7%, 6% and 12.6% for all
subjects, those with UAE 15 mg day-1 and30 mg day-1, respectively. Cox
regression analysis showed that the relative risk for CV events after start of blood
pressure-lowering agents was significantly dependent (P < 0.05) on baseline UAE;
with hazard ratios of 0.87 [95% confidence interval (CI) 0.48, 1.60,P = NS], 0.58
(95% CI 0.36, 0.94,P < 0.05) and 0.37 (95% CI 0.20, 0.68,P < 0.05), for subjects with
UAE < 15,15 and30 mg day-1, respectively. Results adjusted for covariates
were essentially similar.The use of angiotensin converting enzyme inhibitor/
angiotensin-II receptor blocker (ACEi/ARB) treatment tended to be associated
with a more favourable CV prognosis when compared with non-ACEi/ARB
treatment (difference P = 0.06).
CONCLUSIONS
Our results suggest that the efficacy of blood pressure-lowering agents to
prevent CV events is dependent on baseline albuminuria. The higher baseline
albuminuria, the more absolute as well as relative risk reduction can be
achieved. Our data suggest that this may especially be true for ACEi/ARBs. We
caution that this is an observational study, and that these conclusions should
therefore be regarded as hypothesis generating, rather than hypothesis
testing.
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Introduction
Blood pressure-lowering agents are prescribed to lower
the cardiovascular (CV) event rate. Ideally, these agents
should be prescribed preferentially to those subjects at
increased CV risk [1–4]. Risk prediction models have been
developed to estimate the CV risk of an individual, such
as the Framingham Risk Score and the SCORE Risk Model.
These prediction models take into account various risk
factors for CV disease, as well as signs of atherosclerosis-
related end organ damage. In general, these risk predic-
tion models do not contain urinary albumin excretion
(UAE) [5].
In various cross-sectional studies it has been found that
albuminuria is associated with CV risk factors such as age,
gender, blood pressure, cholesterol, glucose, body mass
index (BMI) and smoking [6–13]. Prospective studies have
shown that higher albuminuria levels predict worse CV
outcome, even independent of the above-mentioned risk
factors. Such observations were done not only in subjects
with diabetes and hypertension, but also in the general
population [14–20]. It is therefore tempting to hypothesize
that especially subjects with higher albuminuria levels may
benefit from blood pressure-lowering agents to improve
their CV outcome [21].
We recently completed the PREVEND IT Study, a pro-
spective study in which subjects were randomized to
placebo or the angiotensin converting enzyme inhibitor
(ACEi) fosinopril [22]. To be eligible subjects had to have
albuminuria >15 mg day-1 and normal blood pressure and
cholesterol, as defined by prevailing guidelines for general
practitioners at the start of the study in 1998. In these
subjects, apparently at low CV risk, the ACEi lowered the
incidence of CV events. In subjects with higher baseline
albuminuria the absolute risk reduction with ACE inhibi-
tion was greater. Of more interest was the observation that
also the relative risk (RR) reduction with the ACEi was
found to be dependent on baseline albuminuria: the
higher baseline albuminuria, the greater the RR reduction
[22]. Since the PREVEND IT study is placebo controlled, it is
impossible to ascertain whether the reduction in CV event
rate is due to an ACEi-specific effect, or merely due to the
blood pressure-lowering effect of this drug class. Further-
more, participants in the PREVEND IT study were only
included with persistent albuminuria and therefore it was
not formally tested whether the RR reduction with active
therapy was significantly greater in subjects with high vs.
low albuminuria levels.
To provide answers to these issues we decided to
analyse data obtained in a community-based prospective
cohort study, investigating whether the efficacy of blood
pressure-lowering agents to lower the CV event rate is
dependent on baseline albuminuria. Second, if such an
effect is to be found, to study whether this effect is specific
for agents that interfere with the renin–angiotensin
system [ACE/angiotensin-II receptor blocker (ARBs)] or can
also be observed with other classes of blood pressure-
lowering drugs.
Methods
Study design and population
This analysis uses data of the PREVEND study, a prospective
observational cohort study designed to investigate the
impact of albuminuria on the development of renal and CV
diseases in the general population. The design of the
PREVEND study has been described in detail elsewhere
[13, 23], and can be found on http://www.PREVEND.org.
In summary, participating subjects were selected in 1997
from 40 856 individuals from the general population. A
cohort aged 28–75 years, enriched for higher levels of
albuminuria, was drawn from these individuals. A total of
8592 subjects gave written informed consent and were
included in the baseline screening that took place
between 1997 and 1998. The PREVEND study has been
approved by the local medical ethics committee and
was conducted in accordance with the guidelines of the
Declaration of Helsinki.
For the present analyses those individuals were
included who had detailed pharmacy records on drug use
available, who were at the date of the baseline screening
hypertensive [defined as systolic blood pressure (SBP)
140 and/or diastolic blood pressure (DBP) 90 mmHg
[4]], without a CV disease history and not using blood
pressure-lowering agents (Figure 1). For the remaining
subjects, it was evaluated whether they did or did not
start using blood pressure-lowering drugs during study
follow-up (‘non-users’ and ‘starters’, respectively) (Figure 1).
In both groups the incidence of CV events was studied
during follow-up. Of note, subjects that started using
blood pressure-lowering drugs after a CV event took place
were classified as ‘non-users’, since these subjects had not
been exposed to blood pressure-lowering drugs before
the event occurred.
Measurements and definitions
The baseline screening procedure consisted of a physical
examination and a questionnaire on demographics and
medical history. During the physical examination, weight,
height and blood pressure were measured. BMI was calcu-
lated as weight (kg) divided by the square of height (m2).
SBP and DBP were measured on two occasions in supine
position on the right arm every minute for 10 min, with
an automatic Dinamap XL model 9300 series monitor
(Johnson-Johnson Medical Inc., Tampa, FL, USA). Blood
pressure was calculated as the mean of the last two mea-
surements at both occasions. Mean arterial pressure (MAP)
was assessed as one-third of the SBP and two-thirds of the
DBP. Additionally, fasting blood was drawn for the determi-
nation of total cholesterol, glucose and serum creatinine
levels. Furthermore, for the measurement of albuminuria
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two 24-h urine samples were collected after thorough
oral and written instructions on how to perform urine
collection.
Plasma total cholesterol, plasma glucose and serum
creatinine were determined by Kodak Ectachem dry chem-
istry (Eastman Kodak, Rochester, NY, USA), an automatic
enzymatic method. Serum creatinine was measured by
photometric determination with the Jaffe method without
deproteinization (Merck kgaA, Darmstadt, Germany).
Glomerular filtration rate (eGFR) was estimated using the
Modification of Diet in Renal Disease (MDRD) formula.
Urine albumin concentration (UAC) was determined by
nephelometry (Dade Behring Diagnostic, Marburg,
Germany). Albuminuria is given as the mean UAE in the
two 24-h urine collections (UAE in mg day-1).
Information on drug use
Data on drug use was obtained from the Inter-Action
Data-Base (IADB), which comprises pharmacy-dispensing
data of community pharmacists located in the Nether-
lands [24]. These pharmacies provide the IADB database a
complete listing of patient-specific dispensed drugs [25].
The pharmacy data contain information about patient-
specific drugs dispensed, e.g. the name of a drug, the Ana-
tomical Therapeutical Chemical (ATC) classification, the
date of prescription, the number of days for which a drug
was prescribed, and the number of dispensed defined
daily doses (DDDs). DDDs for blood pressure-lowering
drugs have been defined by the World Health Organiza-
tion, with units intended to represent dosages with
approximately similar efficacy. For example, enalapril
20 mg od has been defined in 1 DDD, as is amlodipine
10 mg od and metoprolol SR 100 mg od [26]. Correcting
for dispensed DDDs in regression analysis allows among
others for comparison of efficacy between drugs within a
class and between classes.
Blood pressure-lowering drug use was defined as at
least one prescription of antihypertensives (ATC = ‘C02’),
diuretics (ATC = ‘C03’), b-blockers (ATC = ‘C07’), calcium-
channel blockers (ATC = ‘C08’) or ACEi/ARBs (ATC = ‘C09’).
Information on drug use was available from at least half a
year before the baseline screening until date of death or
end of follow-up.
Outcome definitions
The primary outcome variable ‘cardiovascular events’ was
defined as a composite end-point consisting of the inci-
dence of CV morbidity or mortality during follow-up.
Follow-up time was defined as the period from the date
of urine collection of the participant to the date of first
CV event, last contact (census) date or 31 December 2005.
In case a person had moved to an unknown destination,
the date on which the person was removed from the
municipal registry was used as census date. Data on CV
morbidity was obtained from PRISMANT, the Dutch
national registry of hospital discharge diagnoses [27].
Causes of death were obtained from the Dutch Central
Bureau of Statistics [28]. All data were coded according to
the International Classification of Diseases (ICD), 9th revi-
sion and the classification of interventions. For this study,
CV events were defined according the Major Adverse Car-
diovascular Events (MACE) criteria as acute myocardial
infarction (ICD-code 410), acute and subacute ischaemic
heart disease (ICD-code 411), subarachnoid haemorrhage
(ICD-code 430), intracerebral haemorrhage (ICD-code
431), other intracranial haemorrhage (ICD-code 432),
occlusion or stenosis of the precerebral (ICD-code 433) or
cerebral arteries (ICD-code 434), coronary artery bypass
grafting or percutaneous transluminal angioplasty, and
other vascular interventions such as percutaneous trans-
luminal angioplasty or bypass grafting of aorta peripheral
vessels.
Statistical analyses
Baseline characteristics are reported as mean and SD for
continuous variables and as a percentage for categorical
variables. Differences in characteristics between starters
on blood pressure-lowering drugs and non-users were
tested for continuous variables by Student’s t-test, for
categorical variables by a c2 test, and for variables
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In our observational analysis, the effect was compared
of starting blood pressure-lowering drugs vs. no use
concerning the incidence of the composite end-point of
CV morbidity and mortality. A crude RR was calculated for
subjects who started blood pressure-lowering drugs
during follow-up for the incidence of the composite
end-point using a univariate Cox regression model and
with subjects not using blood pressure-lowering drugs as
reference category. Multivariate Cox regression models
were built to estimate a RR adjusted for baseline charac-
teristics (age, sex, BMI, smoking, MAP, cholesterol, glucose,
serum creatinine, eGFR, albuminuria, start of lipid-
lowering drugs and start of blood glucose-lowering
drugs). Furthermore, propensity scores were applied in
the regression models (next to other covariates) to
account for differences in characteristics between the
index group (‘starters’) and the reference group (‘non-
users’) [29, 30]. The propensity score for an individual can
be used to reduce bias by indication in observational
studies by means of weighing covariates associated with
start of drugs. In our analyses, the estimated propensity
score for blood pressure-lowering drug use was obtained
from the fit of a logistic regression model including the
following variables: age, sex, BMI, smoking, MAP, choles-
terol, glucose, serum creatinine, eGFR, albuminuria, start
of lipid-lowering drugs and start of blood glucose-
lowering drugs.
This study aimed at investigating the effect of blood
pressure-lowering drugs in preventing CV events in rela-
tion to baseline albuminuria level. Cox proportional
hazards regression analysis was used to assess such a pos-
sible interaction, crude as well as adjusted for covariates.
For this purpose an interaction term was included,‘start of
blood pressure-lowering agent’ times ‘albuminuria level’. In
case the interaction term contributed significantly to the
model, it was decided that the efficacy of blood pressure-
lowering agents depends on baseline albuminuria and
further analyses were to follow. In the first analysis, the
threshold defining elevated albuminuria was set at a UAE
level of 15 mg day-1, consistent with previous work [22]. An
additional analysis was performed in subjects with albu-
minuria 30 mg day-1. Further analyses were conducted
investigating first the effect of the level of drug exposure,
and second the efficacy of ACEi/ARBs vs. non-ACEi/ARB
agents in preventing CV events. For the analysis with
respect to blood pressure-lowering drug exposure,
patient-specific total number of prescribed DDDs was cal-
culated and divided by total days of study follow-up from
date of first screening until the date of a first event, or until
the census date, or until 31 December 2005. Exposure
is expressed as average number of DDDs per day
(DDDs day-1).
All analyses were conducted using the statistical
package SPSS 14.0 (SPSS Inc., Chicago, IL, USA). A P-value




Of the PREVEND cohort consisting of 8592 subjects, com-
plete pharmacy data were available for 8296 participants
(Figure 1). Subjects with normal blood pressure (<140/
90 mmHg) and with a CV disease history were excluded
(n = 6526). Out of the 1770 subjects with elevated blood
pressure, 585 participants received at least one prescrip-
tion of a blood pressure-lowering drug during the half-
year period before the baseline screening and were
therefore excluded. Of the remaining 1185 subjects fol-
lowed in this observational study, 765 started and 420 did
not start using blood pressure-lowering drugs during
follow-up (Figure 1).
The baseline characteristics of these latter two groups
are reported in Table 1. For this table subjects were divided
into different groups based on albuminuria level (UAE) and
whether or not they started use of blood pressure-
lowering drugs after the baseline screening. Those who
started use of blood pressure-lowering drugs had signifi-
cantly higher age and blood pressure, and more frequently
started use of lipid-lowering and blood glucose-lowering
drugs compared with the ‘non-user’ group, both in
the normal (UAE < 15 mg day-1) and the elevated (UAE
15 mg day-1) albuminuria groups. Furthermore, in sub-
jects with normal albuminuria the ‘starter’ group had
significantly higher glucose levels, and in subjects with
elevated albuminuria ‘starters’ had a lower eGFR.
Follow-up data
Total follow-up for this observational study until occur-
rence of a CV disease event, census date or until the end of
the study period amounted to 8378 person-years, with a
mean follow-up of 7.1 years (SD 1.6) per subject included.
Table 2 shows the number of (first) CV events that occurred
during follow-up, both with respect to the composite end-
point and as the individual components. As the current
study was designed as a ‘time-to-first-event’ study, only
first events are shown.The composite end-point of CV mor-
bidity and mortality occurred in 122 (11.2%) subjects, with
42 (6.9%) in the normal albuminuria group (n = 611) and 80
(13.9%) in the elevated albuminuria group (n = 574). These
data show that participants with elevated albuminuria
have a higher risk of reaching the composite end-point
compared with subjects without elevated albuminuria,
with a crude RR of 2.03 [95% confidence interval (CI) 1.42,
2.90].
Figure 2 shows the results on the difference in absolute
risk for the composite end-point for ‘starters’ on vs. ‘non-
users’ of blood pressure-lowering drugs. In the overall
population, start of blood pressure-lowering drugs was
associated with a difference in absolute risk for CV events
of 0.7% vs. no use, which was not statistically significant
(P = 0.80). For the subgroup of subjects with normoalbu-
minuria, comparable results were found with a difference
C. Boersma et al.
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in absolute risk of 0.6% (P = 0.87). In contrast, the higher
baseline albuminuria, the more pronounced the absolute
risk reduction for the composite end-point in ‘starters’ vs.
‘non-users’ of blood pressure-lowering drugs. In the sub-
group of subjects with albuminuria 15 mg day-1 the
absolute risk amounted 18.6% (‘non-users’) vs. 12.6%
(‘starters’), with a difference in absolute risk of 6.0%
(P = 0.11), whereas in the subgroup of subjects with
albuminuria30 mg day-1 these figures were 24.6% and
12.0%, respectively (absolute difference 12.6%, P <
0.05).
Table 3 shows the unadjusted and adjusted hazard
ratios (HRs) for the composite CV end-point of subjects
who started use of blood pressure-lowering drugs during
follow-up with subjects who did not use such drugs as
reference category. For the overall population a statistically
nonsignificant difference in the composite end-point was
found for subjects starting on blood pressure-lowering
drugs compared with non-users (HR = 0.87; 95% CI 0.61,
1.26). After adjustment for baseline characteristics, this dif-
ference in risk increased and was statistically significant
(HR = 0.54; 95% CI 0.36, 0.83, P < 0.01). Further adjustment
also with propensity score left this unchanged (HR = 0.52;
95% CI 0.34, 0.80, P < 0.01).
A possible interaction between blood pressure-
lowering drug use and albuminuria on CV outcome was
tested in the overall crude, as well as adjusted Cox propor-
tional hazards models. The ‘start of blood pressure-
lowering agent’ times ‘albuminuria level’ interaction term
was significantly associated with the outcome in all
Table 1
Baseline characteristics
UAE < 15 mg day-1 (n = 611)
P-value










Age, years (SD) 52.9 (12.5) 56.0 (11.3) 0.001* 55.4 (12.4) 58.6 (10.7) <0.01*
Gender, male, % 56.0 54.7 0.74† 72.1 62.9 0.06†
BMI, kg m-2, (SD) 27.1 (3.9) 27.1 (3.8) 0.93* 28.4 (4.9) 28.5 (4.4) 0.88*
Smoking, % 34.7 38.4 0.34† 42.6 42.9 0.95†
DBP, mmHg (SD) 80.6 (7.5) 83.7 (7.3) <0.001* 82.4 (7.4) 86.9 (9.4) <0.001*
SBP, mmHg (SD) 148.1 (8.3) 154.0 (13.1) <0.001* 151.2 (10.3) 159.5 (15.9) <0.001*
MAP, mmHg (SD) 103.1 (6.5) 107.2 (7.4) <0.001* 105.3 (7.1) 111.1 (10.0) <0.001*
Plasma cholesterol, mmol l-1 (SD) 6.0 (1.3) 5.9 (1.3) 0.40* 5.8 (1.3) 6.0 (1.3) 0.28*
Plasma glucose, mmol l-1 (SD) 4.9 (1.0) 5.0 (1.0) <0.05* 5.5 (1.9) 5.5 (1.9) 0.68*
Serum creatinine, mmol l-1 (SD) 83.3 (15.2) 83.6 (16.3) 0.77* 86.6 (18.8) 86.9 (18.7) 0.84*
eGFR, ml min-1 1.73 m-2 (SD) 80.6 (14.4) 78.7 (14.3) 0.10* 80.3 (14.1) 77.3 (14.7) <0.05*
Albuminuria, mg day-1 (95% CI) 8.5 8.9 0.07‡ 30.7 35.5 0.06‡
(3.1, 14.8) (0, 15.0) (15.0, 763.9) (15.1, 2688.9)
Start of lipid lowering drugs, % 11.3 35.0 <0.001† 20.9 48.3 <0.001†
Start of blood glucose-lowering drugs, % 3.1 10.0 <0.001† 6.2 17.1 <0.05†
Continuous variables are presented as mean and standard deviation (SD) and categorical variables as percentage. Urinary albumin excretion is given as geometric mean and 95%
CI. BMI, Body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; MAP, mean arterial blood pressure; eGFR, estimated glomerular filtration rate. *t-test. †c2 test.
‡Mann–Whitney test.
Table 2
Incidence of the composite cardiovascular end-point, and individual components in all subjects, stratified according to albuminuria class. Since analyses are
time-to-first event based, for participants included only first events during follow-up are presented
All subjects
(n = 1185)
UAE < 15 mg day-1
(n = 611)
UAE  15 mg day-1
(n = 574)
Composite end-point (%) 122 (11.2) 42 (6.9) 80 (13.9)
Individual components:
Cardiovascular death 3 1 2
Nonfatal events
– Cardiac* 78 29 49
– Cerebrovascular† 31 11 20
– Peripheral disease‡ 10 1 9
*Cardiac disease events: myocardial infarction, ischaemic heart disease, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty. †Cerebrovascular disease
events: subarachnoid haemorrhage, intracerebral haemorrhage, occlusion and stenosis of precerebral arteries, occlusion of cerebral arteries. ‡Peripheral vascular disease events: aorta
peripheral bypass surgery, percutaneous transluminal femoral angioplasty.
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models (P < 0.05), indicating that the benefit of blood
pressure-lowering drugs was greater in subjects with
higher albuminuria levels.
Cox proportional hazards regression analyses based on
subgroups confirmed that the RR for CV events with blood
pressure-lowering drug use depends on baseline albumin-
uria level with unadjusted HRs for all subjects being 0.87
(95% CI 0.61, 1.26, P = NS), for subjects with UAE
< 15 mg day-1 0.87 (95% CI 0.48, 1.60, P = NS), for subjects
with UAE = 15 mg day-1 0.58 (95% CI 0.36, 0.94, P < 0.05)
and for subjects with UAE = 30 mg day-1 0.37 (95% CI 0.20,
0.68,P < 0.05).Table 3 shows that the results are essentially
similar after adjustment for age, sex, baseline characteris-
tics, start of lipid-lowering and blood glucose-lowering
agents and propensity scores.These results are graphically
depicted in Figure 3.
Table 4 provides data on only subjects starting blood
pressure-lowering drugs during follow-up. It shows that
subjects with higher baseline albuminuria had higher
exposure to blood pressure-lowering drugs. The role of
exposure to such drugs was investigated, showing that
high exposure (average number of DDDs day-1 0.75) was
associated with lower chance to reach the composite end-
point compared with low exposure (average number of
DDDs day-1 < 0.75) (Table 3). Since this may influence the
results obtained, the RRs to reach the composite end-point
denoted in Table 3 are in the final model also adjusted for
level of exposure to blood pressure-lowering drugs.
The question whether agents that interfere with the
renin–angiotensin system (ACEi/ARB) differ from other
blood pressure-lowering drugs in their efficacy in prevent-
ing CV events is also addressed in Table 3. It shows that
subjects using only ACEi/ARB treatment had a HR of 0.63 to
reach the composite end-point compared with those
receiving non-ACEi/ARB treatment only. Whereas this dif-
ference is not statistically significant in the crude analysis,
there is a trend towards statistical significance after adjust-
ment for baseline characteristics, propensity score and
level of exposure (P = 0.06). As found for the whole group
of blood pressuring-lowering drugs, the effect of ACEi/ARB
treatment turned out to be significantly dependent on
baseline albuminuria (P < 0.05 for the interaction term
‘start of ACEi/ARB’ times ‘albuminuria level’). Such an asso-
ciation was not found for non-ACEi/ARB treatment.
Discussion
Besides the finding that blood pressure-lowering agents
are effective in ameliorating the CV outcome, our observa-
tional data show that in hypertensive subjects without a
CV disease history the risk of reaching a CV event during
follow-up is dependent on baseline albuminuria. The
higher baseline albuminuria in such subjects, the higher
the risk for CV disease. As expected, start of treatment
with blood pressure-lowering drugs is associated with a
decrease in CV risk, with absolute risk reduction being
superior in subjects with higher baseline albuminuria and
corresponding number needed to treat (NNT) to prevent
one CV event of 153 vs. 17 for those subjects with
UAE < 15 mg day-1 and UAEmg day-1 respectively. For
subjects with UAE < 30 mg day-1 and UAE 30 mg day-1
NNTs were 111 and 8, respectively. More interesting,
however, is our finding that the RR reduction for CV events
with blood pressure-lowering agents is also dependent on
baseline albuminuria.The higher baseline albuminuria, the
better the RR reduction. Furthermore, the CV protective
effect of ACEi/ARBs in subjects with higher albuminuria
seems to be better than that of other blood pressure-
lowering agents. However, possible interindividual varia-
tion in responses to different types and doses of blood
pressure-lowering agents could have influenced these
results. Further research should be directed at blood
pressure-lowering efficacy, correcting for these potential
differences, before definite conclusions may be drawn.
How do these data compare with the literature? Several
epidemiological studies have shown that albuminuria is a
valuable risk marker for CV disease in various patient popu-
lations,such as diabetics and hypertensives,and even in the
general population [14–20]. Numerous randomized con-
trolled trials have shown that blood pressure-lowering
agents improve CV outcome [31, 32]. Little is known,
however, of a possible interaction between albuminuria
and the cardioprotective efficacy of blood pressure-
lowering agents. As discussed in the Introduction, the





































Absolute risk for the incidence of the combined end-point of cardio-
vascular morbidity and cardiovascular death for subjects who started
(‘starters’, ()) and did not start (‘non-users’, ()) treatment with blood
pressure-lowering drugs during follow-up. UAE, Urinary albumin excre-
tion. N indicates the number of subjects in each group. Unadjusted
P-values* calculated using a c2 test. *P-values representing the signifi-
cance level after follow-up correction are P = 0.47, P = 0.66, P < 0.05 and
P < 0.05 for all subjects, and those subjects with UAE < 15 mg day-1,
UAE 15 mg day-1 and UAE 30 mg day-1, respectively
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placebo resulted in more absolute and relative CV risk
reduction compared with placebo in subjects with higher
pretreatment albuminuria [22]. Subgroup analysis of the
HOPE Study has provided similar results [33]. This study
included subjects at high CV risk and randomized them to
placebo or the ACEi ramipril. The RR reduction obtained
with the ACEi was greater in subjects who were microalbu-
minuria positive compared with subjects who were
microalbuminuria negative. However, both the PREVEND IT
study and the HOPE trial involved post hoc analyses and
their observations were not formally tested. This was why
we performed the present analyses with a predefined ques-
tion.Another study has since been published that relates to
these findings.The PEACE trial found that the ACEi trandola-
pril did not improve survival in the overall study population
of patients with stable coronary artery disease and pre-
served systolic function [34]. However, in the subgroup of
patients with reduced renal function the use of trandolapril
was associated with a significant reduction in total mortal-
ity, as well as in CV outcome. It thus appears that, besides
higher albuminuria, another marker of chronic kidney
damage, i.e. lower renal function, shows an interaction with
the use of blood pressure-lowering agents on outcome.
All three above-mentioned controlled trials (PREVEND-
IT, HOPE, PEACE) concerned studies that randomized
patients to placebo or an ACEi. Thus, it cannot be ascer-
tained whether the interaction between treatment effect
and albuminuria is specific to ACEis, or is just the result of
blood pressure lowering of these drugs per se. In this
Table 3











Non-users 420 45 (10.7) 1.00 1.00 1.00
Starters 765 77 (10.1) 0.87 (0.61, 1.26) 0.54 (0.36, 0.83) 0.52 (0.34, 0.80)
UAE < 15 mg day-1
Non-users 291 21 (7.2) 1.00 1.00 1.00
Starters 320 21 (6.6) 0.87 (0.48, 1.60) 0.55 (0.28, 1.10) 0.56 (0.28, 1.12)
UAE  15 mg day-1
Non-users 129 24 (18.6) 1.00 1.00 1.00
Starters 445 56 (12.6) 0.58 (0.36, 0.94) 0.44 (0.26, 0.75) 0.42 (0.24, 0.72)
UAE  30 mg day-1
Non-users 65 16 (24.6) 1.00 1.00 1.00
Starters 258 31 (12.0) 0.37 (0.20, 0.68) 0.33 (0.16, 0.69) 0.31 (0.15, 0.65)
Starters only
Low exposure < 0.75 DDDs day-1 453 48 (10.6) 1.00 1.00 1.00
High exposure  0.75 DDDs day-1 312 29 (9.3) 0.87 (0.55, 1.37) 0.72 (0.42, 1.23)¶ 0.70 (0.40, 1.20)¶
Starters only
Non-ACEi/ARB only 219 29 (13.2) 1.00 1.00 1.00
ACEi/ARB only 155 13 (8.3) 0.63 (0.33, 1.22) 0.51 (0.25, 1.01)†† 0.51 (0.26, 1.03)††
*Number of persons and percentage with the composite end-point (cardiovascular morbidity or mortality). †Crude relative risk without any adjustment for baseline characteristics.
‡Adjusted for age, sex, body mass index (BMI), smoking, mean arterial pressure (MAP), cholesterol, glucose, serum creatinine, estimated glomerular filtration rate (e-GFR), urinary
albumin excretion (UAE), start of lipid-lowering drugs and start of blood glucose-lowering drugs. §Adjusted for all previously mentioned variables including propensity scores.
¶Additional adjustment for exposure to type of blood pressure-lowering drug (categorized variable: non-ACEi/ARB only, ACEi/ARB only or both types). ††Additional adjustment level
























Hazard rates for the composite end-point of cardiovascular morbidity and
cardiovascular mortality for subjects who started use of blood pressure-
lowering drugs vs. subjects who did not start use of such agents. UAE,
Urinary albumin excretion. On the left unadjusted hazard rates. In the
middle adjusted hazard rates with adjustment for age, sex, body mass
index (BMI), smoking, mean arterial pressure (MAP), cholesterol, glucose,
serum creatinine, estimated glomerular filtration rate (eGFR), UAE, start of
lipid-lowering drugs and blood glucose-lowering drugs. On the right
adjusted hazard rates with adjustment for all previously mentioned vari-
ables, including propensity scores. P-values calculated using a c2 test
(UAE < 15 mg day,; UAE 15 mg day,; UAE 30 mg day, )
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respect, our findings are of interest, suggesting that indeed
ACEi/ARBs are superior to non-ACEi/ARBs in improving CV
outcome in subjects with higher levels of albuminuria. A
similar suggestion has been made by Reddan et al., who
found in subjects with an acute coronary syndrome an
interaction between the effect of ACEis and glomerular
filtration rate on 90-day mortality rate [35].The lower renal
function, the more protective ACE inhibition. In their analy-
sis such an interaction was not found for other blood
pressure-lowering drugs.
What might be the mechanism of our findings? Albu-
minuria has been shown to be closely correlated with
endothelial damage due to atherosclerosis [36, 37]. In sub-
jects with higher levels of albuminuria it is to be expected
that a medical intervention that inhibits the progressive
process of atherosclerosis, such as blood pressure lower-
ing, will effectively prevent CV events. In contrast, subjects
with low levels of albuminuria supposedly have little
atherosclerosis. It might well be that in these latter subjects
CV events are predominantly atherothrombosis related. It
is less expected that the incidence of such events can be
ameliorated by blood pressure lowering. Unfortunately,
our dataset does not allow an in-depth analysis of this
hypothesis, since it does not contain information on the
pathophysiological origin of the CV events registered
during follow-up.
Our present study, together with the supporting data
from literature, may have important consequences. They
suggest that in a subject without elevated levels of
albuminuria on average the absolute risk for a CV event is
relatively low, and that prescription of blood pressure-
lowering drugs will hardly affect this absolute risk. In con-
trast, in hypertensive subjects with elevated levels of
albuminuria the absolute risk for a CV event is high. Fur-
thermore, it could be expected that in such patients the
prescription of blood pressure-lowering agents, and espe-
cially ACEi/ARB, will result in significant relative, as well as
absolute risk reduction.
A limitation of this study is its design. In contrast to
randomized clinical trials (RCTs), observational studies are
not the standard method to assess efficacy of medical
intervention. Bias by indication and residual (unknown)
confounding may play a role in observational studies.
However, at the moment there are no RCTs designed to
investigate prospectively the interaction between albu-
minuria levels and efficacy of blood pressure-lowering
drugs. Furthermore, most RCTs have rigid inclusion and
exclusion criteria that result in patient populations that are
sometimes difficult to compare with broader groups of
patients in real life. Therefore, results from clinical trial set-
tings and a ‘real-world’ observational setting as in this
study are of clinical relevance and should be regarded as
additive to obtain a full picture of the effectiveness of
blood pressure-lowering drugs [38]. To minimize the
potential role of bias by indication a score was calculated
for the propensity to be prescribed blood pressure-
lowering medication. Our models were adjusted for this
propensity score, as recommended for observational
studies investigating the efficacy of medical intervention
[29, 30]. Nevertheless, given its observational design, this
study should be regarded as hypothesis generating rather
than as hypothesis testing. Prospective RCTs, with a priori
defined subgroup analyses according to UAE level and
with tailored sample size, are needed to verify our findings.
The level of exposure to blood pressure-lowering drugs
is another theoretical limitation. We noticed that the
higher the level of albuminuria, the greater the level of
exposure to blood pressure-lowering drugs. Theoretically,
this could explain the higher efficacy of such drugs in pre-
venting CV events in subjects with elevated albuminuria.
However, in case our analyses were limited to only subjects
with high exposure, it was again shown that efficacy of
blood pressure was dependent on albuminuria before
start of treatment with adjusted HRs of 0.46 and 0.27 (both
P < 0.01) for UAE 15 mg day-1 and UAE 30 mg day-1,
respectively. Furthermore, in subgroup analyses adjust-
Table 4
Exposure to blood pressure-lowering drugs (at least one prescription*)
All subjects
(n = 765)
UAE < 15 mg day-1
(n = 320)
UAE  15 mg day-1
(n = 445)
All BPLDs
<0.75 DDDs day-1 453 (59.2%) 230 (71.9%) 223 (50.1%)
0.75 DDDs day-1 312 (40.8%) 90 (28.1%) 222 (49.9%)
Non-ACEi/ARB only
<0.75 DDDs day-1 174 (79.5%) 100 (87.0%) 74 (71.2%)
0.75 DDDs day-1 45 (20.5%) 15 (13.0%) 30 (28.8%)
ACEi/ARB only
<0.75 DDDs day-1 119 (76.8%) 48 (92.3%) 71 (68.9%)
0.75 DDDs day-1 36 (23.2%) 4 (7.7%) 32 (30.1%)
*Subjects included can have received different blood pressure-lowering drugs during follow-up. BPLD, Blood pressure-
lowering drugs; DDDs day-1, defined daily dose per day; ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; UAE,
urinary albumin excretion.
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ment was made not only for baseline characteristics and
propensity score, but also for level of exposure. We there-
fore think that our findings are robust.
In conclusion, our study has indicated that the efficacy
of blood pressure-lowering agents to prevent CV events is
dependent of the level of albuminuria before start of such
treatment. The higher baseline albuminuria, the better the
relative and absolute risk reduction for CV events with
these drugs.These data suggest also that the CV protective
effect of ACEi/ARBs in subjects with higher albuminuria
may be better than that of other blood pressure-lowering
agents. We caution that this was an observational study,
and that these conclusions should therefore be regarded
as hypothesis generating, rather than hypothesis testing.
The PREVEND Study has been made possible by grants of the
Dutch Kidney Foundation.We thank Dade Behring (Marburg,
Germany) for supplying equipment (BehringNephelometer II)
and reagents for nephelometric measurement of urinary
albumin concentration.
REFERENCES
1 Guidelines Committee. 2003 European Society of
Hypertension – European Society of Cardiology guidelines
for the management of arterial hypertension. J Hypertens
2003; 21: 1011–53.
2 Withworth JA; World Health Organization International
Society of Hypertension Writing Group. 2003 World Health
Organization (WHO) /International Society of Hypertension
(ISH) statement on management of hypertension.
J Hypertens 2003; 21: 1983–92.
3 Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM,
Kiowski W, Kjeldsen S, Lüscher T, Mallion JM, Mancia G,
Poulter N, Rahn KH, Rodicio JL, Ruilope LM, van Zwieten P,
Waeber B, Williams B, Zanchetti A;ESH/ESC Hypertension
Guidelines Committee. Practice guidelines for primary care
physicians: ESH/ESC hypertension guidelines. J Hypertens
2003; 22: 1779–86.
4 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA,
Izzo JL Jr, Roccella EJ;National Heart, Lung, and Blood
Institute Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure; National
High Blood Pressure Education Program Coordinating
Committee. The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure: the JNC 7 report. JAMA
2003; 289: 2560–72.
5 Bakris G. Inclusion of albuminuria in hypertension and heart
guidelines. Kidney Int Suppl 2004; 92: S124–5.
6 Pedrinelli R, Dell’Omo G, Di Bello V, Pontremoli R, Mariani M.
Microalbuminuria, an integrated marker of cardiovascular
risk in essential hypertension. J Hum Hypertens 2002; 16:
79–89.
7 Terpstra WF, May JF, Smit AJ, de Graeff PA, Crijns HJ.
Microalbuminuria is related to marked end-organ damage
in previously untreated, elderly, hypertensive patients. Blood
Press 2002; 11: 84–90.
8 Verhave JC, Hillege HL, Burgerhof JGM, Navis G, de Zeeuw D,
de Jong PE; Prevend Study Group. Cardiovascular risk factors
are differently associated with urinary albumin excretion in
men and women. J Am Soc Nephrol 2003; 14: 1330–5.
9 Tsioufis C, Dimitriades K, Antoniades D, Stefanadis C,
Kallikazaros I. Inter-relationship of micro-albuminuria with
the other surrogates of atherosclerotic cardiovascular
disease in hypertensive subjects. Am J Hypertens 2004; 17:
470–6.
10 Palatini P. Microalbuminuria in hypertension. Curr Hypertens
Rep 2003; 5: 208–14.
11 Campese VM, Bianchi S, Bigazzi R. Association between
hyperlipidemia and microalbuminuria in essential
hypertension. Kidney Int Suppl 1999; 56: S10–3.
12 Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F,
Tirotta A, Ruello N, Tomolillo C, Castello C, Grillo G, Sacchi G,
Deferrari G. Prevalence and clinical correlates of
microalbuminuria in essential hypertension. The MAGIC
Study. Hypertension 1997; 30: 1135–43.
13 Hillege HL, Janssen WMT, Bak AA, Diercks GF, Grobbee DE,
Crijns HJ, van Gilst WH, de Zeeuw D, de Jong PE; Prevend
Study Group. Microalbuminuria is common, also in a
nondiabetic, nonhypertensive population, and an
independent indicator of cardiovascular risk factors and
cardiovascular morbidity. J Intern Med 2001; 249: 519–26.
14 Rossing P, Hougaard P, Borch-Johnsen K, Parving HH.
Predictors of mortality in insulin dependent diabetes:
10 year observational follow up study. BMJ 1996; 313:
779–84.
15 Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W,
Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C,
Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F,
Goldhaber S, Lewis EJ, Pfeffer MA. Predictors of
cardiovascular events in patients with type 2 diabetic
nephropathy and hypertension: a case for albuminuria.
Kidney Int 2004; 66 (Suppl. 92): S50–5.
16 Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D,
van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE,
de Jong PE, Prevention of Renal and Vascular Endstage
Disease (Prevend) Study Group. Urinary albumin excretion
predicts cardiovascular and noncardiovascular mortality in
the general population. Circulation 2002; 106: 1777–82.
17 Jager A, Kostens PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM,
Bouter JM, Stehouwer CD. Microalbuminuria and peripheral
arterial disease are independent predictors of cardiovascular
and all-cause mortality, especially among hypertensive
subjects: five year follow-up of the Hoorn Study. Arterioscl
Thromb Vasc Biol 1999; 19: 617–24.
18 Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF,
Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S,
Yusuf S, Hope Study Investigators. Albuminuria and risk of
cardiovascular events, death, and heart failure in diabetic
and nondiabetic individuals. JAMA 2001; 286: 421–6.
Albuminuria dependent effect of BP-lowering agents
Br J Clin Pharmacol / 65:5 / 731
19 Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE,
Wareham NJ. A prospective study of microalbuminuria and
incident coronary heart disease and its prognostic
significance in a British population: the EPIC-Norfolk study.
Am J Epidemiol 2004; 159: 284–93.
20 de Jong PE, Curhan GC. Screening, monitoring, and
treatment of albuminuria: public health perspectives. J Am
Soc Nephrol 2006; 17: 2120–6.
21 Basi S, Lewis JB. Microalbuminuria as a target to improve
cardiovascular and renal outcomes. Am J Kidney Dis 2006;
47: 927–46.
22 Asselbergs FW, Diercks GFH, Hillege HL, van Boven AJ,
Janssen WM, Voors AA, de Zeeuw D, de Jong PE,
van Veldhuisen DJ, van Gilst WH, Prevention of Renal and
Vascular Endstage Disease Intervention Trial (Prevend IT)
Investigators. Effects of fosinopril and pravastatin on
cardiovascular events in subjects with microalbuminuria.
Circulation 2004; 110: 2809–16.
23 Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G,
de Zeeuw D, de Jong PE. Urinary albumin excretion is
associated with renal function abnormalities in a
nondiabetic population. J Am Soc Nephrol 2000; 11: 1882–8.
24 Pharmacy-dispensing database of IADB.nl. Available at
http://www.iadb.nl (last accessed 20 July 2007)
25 Monster TB, Janssen WM, de Jong PE,
de Jong-van den Berg LT, Prevend Study Group. Pharmacy
data in epidemiological studies: an easy to obtain reliable
tool. Pharmcoepidemiol Drug Saf 2002; 11: 379–84.
26 WHO Collaborating Centre for Drugs Statistics Methodology.
ATC/DDD Index 2005. Available at http://www.
whocc.no/atcddd (last accessed: 8 August 2007)
27 Prismant. National LHR information [in Dutch]. Available at
http://www.prismant.nl [data specifically requested] (Last
accessed: 8 June 2007)
28 http://www.cbs.nl/nl-NL/default.htm
29 Rosenbaum PR, Rubin DB. Reducing bias in observational
studies using subclassification on propensity score. J Am
Stat Assoc 1984; 79: 516–24.
30 Cook EF, Goldman L. Asymmetric stratification. An outline for
an efficient method for controlling confounding in cohort
studies. Am J Epidemiol 1988; 127: 626–39.
31 Collins R, Peto R, Macmahon S, Hebert P, Fiebach NH,
Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH.
Blood pressure, stroke, and coronary heart disease. Part 2,
Short-term reductions in blood pressure: overview of
randomised drug trials in their epidemiological context.
Lancet 1990; 335: 827–38.
32 Neal B, Macmahon S, Chapman N;Blood Pressure Lowering
Treatment Trialists’ Collaboration. Effects of ACE inhibitors,
calcium antagonists, and other blood-pressure-lowering
drugs: results of prospectively designed overviews of
randomised trials. Lancet 2000; 356: 1955–64.
33 Yusuf S, Sleight G, Pogue J, Bosch J, Davies R, Dagenais G; the
Heart Outcomes Prevention Evaluation Study Investigators.
Effects of an angiotensin-converting-enzyme inhibitor,
ramipril, on cardiovascular events in high-risk patients.
N Engl J Med 2000; 342: 145–53.
34 Solomon SD, Rice MM, Jablonski KA, Jose P, Domanski M,
Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA,
Braunwald E;Prevention of Events with ACE inhibition
(PEACE) Investigators. Renal function and effectiveness of
angiotensin-converting enzyme inhibitor therapy in patients
with chronic stable coronary disease in the prevention of
events with ACE inhibition (PEACE) trial. Circulation 2006;
114: 26–31.
35 Reddan DN, Szczech L, Bhapkar MV, Moliterno DJ, Califf RM,
Ohman EM, Berger PB, Hochman JS, van der Werf F,
Harrington RA, Newby LK. Renal function, concomitant
medication use and outcomes following acute coronary
syndromes. Nephrol Dial Transplant 2005; 20: 2105–12.
36 Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T,
Kofoed-Enevoldsen A. Albuminuria reflects widespread
vascular damage. The Steno hypothesis. Diabetologia 1989;
32: 219–26.
37 Verhave JC, Hillege HL, Burgerhof JG, Gansevoort RT,
de Zeeuw D, de Jong PE; Prevend Study Group. The
association between atherosclerotic risk factors and renal
function in the general population. Kidney Int 2005; 67:
1967–73.
38 Vandenbroucke JP. Benefits and harms of drug treatments.
Observational studies and randomised trials should learn
from each other. BMJ 2004; 329: 2–3.
C. Boersma et al.
732 / 65:5 / Br J Clin Pharmacol
